Envoy Medical, Inc. 8-K

What Happened
Envoy Medical, Inc. (COCH) filed an 8‑K (May 18, 2026) reporting results from its May 12, 2026 Annual Meeting. Stockholders approved amendments to the company’s 2023 Equity Incentive Plan (adding 6,000,000 shares) and 2023 Employee Stock Purchase Plan (adding 1,200,000 shares); both amendments became effective at the time of approval. Stockholders also elected two Class III directors — Brent T. Lucas and Susan J. Kantor — ratified EisnerAmper, LLP as the independent auditor for 2026, approved executive compensation on an advisory basis, and approved for Nasdaq compliance the issuance of warrants and underlying Common Stock from a Feb 12, 2026 transaction.

Key Details

• Equity plan increases approved: 6,000,000 additional shares for the Equity Incentive Plan; 1,200,000 additional shares for the Employee Stock Purchase Plan (effective upon approval).
• Director elections: Brent T. Lucas — For: 47,216,205; Withheld: 70,530; Broker non‑votes: 655,966. Susan J. Kantor — For: 46,961,571; Withheld: 325,164; Broker non‑votes: 655,966.
• Auditor ratification: EisnerAmper, LLP ratified — For: 47,933,597; Against: 3,434; Abstain: 5,670.
• Nasdaq compliance vote for previously issued warrants (2/12/2026 transaction): For: 47,217,476.89; Against: 42,625; Abstain: 26,634; Broker non‑votes: 655,966.

Why It Matters
Approving the additional shares gives Envoy Medical flexibility to grant more stock awards and ESPP shares, which management can use for hiring, retention and employee compensation. That flexibility can support growth but may lead to future dilution if and when awards are granted and exercised. Re‑electing board members and ratifying the auditor maintain governance continuity. The Nasdaq‑rule approval clears a procedural step related to warrants issued in February 2026, removing a potential listing compliance issue.